AZD5335 vs. Mirvetuximab Soravtansine in FRa-high and AZD5335 vs. Chemotherapy in FRa-low Platinum-resistant Ovarian Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Epistemonikos ID: dc7849beb1728ae0e417353cae47e9e283667e54
First added on: Oct 21, 2025